GD-19 and GD-20 Successfully Complete Phase I Clinical Trials

GD-19 and GD-20 have successfully completed Phase I clinical trials. All SAD and MAD cohorts demonstrated good tolerability and favorable safety profiles, with no serious adverse events (SAEs) observed. Treatment-emergent adverse events (TEAEs) were generally mild to moderate in severity.